Moderna (MRNA) announces US FDA will initiate review of its investigational seasonal influenza vaccine submission; FDA assigned a prescription drug user fee act goal date of August 5th, 2026
Importance
Level 1
#FDA#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#MODERNA INC#MRNA#US EQUITIES